Immunome Inc Stock Price, News & Analysis

Immunome, Inc. (Nasdaq: IMNM) will participate in a fireside chat hosted by Cantor Fitzgerald's Brian Cheng on December 8, 2021, at 1:00 p.m. ET, aimed at institutional clients. The event will be accessible via webcast, with a replay available on Immunome's website for 30 days following the live presentation.

Immunome utilizes its proprietary human memory B cell platform to develop innovative antibody therapeutics focusing on oncology and infectious diseases, including COVID-19.

Immunome expects its antibody cocktail, IMM-BCP-01, to be effective against the Omicron variant of SARS-CoV-2. The company is performing laboratory testing to confirm this, with results anticipated in January 2022. IMM-BCP-01 targets three distinct epitopes, enhancing its potential resilience against mutations. The cocktail approach aims to improve viral neutralization, as demonstrated in preclinical tests against other variants. Immunome is advancing IMM-BCP-01 towards clinical trials, pending regulatory approval.

Immunome, Inc. (NASDAQ: IMNM) has submitted an Investigational New Drug (IND) application to the U.S. FDA for IMM-BCP-01, a novel three-antibody cocktail targeting SARS-CoV-2. This submission marks a significant milestone for Immunome as they prepare to conduct clinical studies. Preclinical testing shows that IMM-BCP-01 effectively reduces viral load and encompasses broad coverage against various COVID-19 variants. The project is funded by the U.S. Department of Defense, emphasizing its public health importance as COVID-19 continues to pose a threat.

Immunome, Inc. (Nasdaq: IMNM) made progress in its antibody development, notably with IMM-BCP-01, targeting SARS-CoV-2 variants Lambda and Delta Plus. The company plans to submit an IND for IMM-BCP-01 this quarter, alongside anticipated topline data in H1 2022. Financially, for Q3 2021, R&D expenses reached $4.5M, while G&A expenses were $3.2M, leading to a net loss of $7.7M. As of September 30, 2021, cash reserves stood at $56.3M, indicating sufficient resources for ongoing projects.

Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company specializing in first-in-class antibody therapeutics, announced that its President and CEO, Purnanand Sarma, Ph.D., will present at the Stifel Healthcare Conference on November 15, 2021, at 8:00 a.m. ET. Interested listeners can access the live audio webcast via the Investor Relations section of Immunome's website, with a replay available for 30 days post-event. Immunome focuses on developing therapies for oncology and infectious diseases, including COVID-19, leveraging its proprietary human memory B cell platform.

Immunome (Nasdaq: IMNM) has submitted a preprint manuscript detailing the preclinical efficacy of its SARS-CoV-2 antibody cocktail, IMM-BCP-01. This cocktail includes three monoclonal antibodies targeting regions of the spike protein, showing significant viral load reduction in infected hamsters. In tests, IMM-BCP-01 demonstrated a potent reduction of live viral titers by approximately 3.2 - 4 logs. This research indicates broad protective capabilities against multiple variants, supporting the potential for non-intravenous delivery in humans.

Immunome, Inc. (Nasdaq: IMNM) presented findings on its anti-interleukin-38 monoclonal antibody program at the 2021 AACR-NCI-EORTC International Conference. The presentation revealed that the antibody effectively binds to IL-38, preventing its interaction with receptors and enhancing myeloid cell activity in vitro. In murine tumor models, the antibody significantly inhibited tumor growth. This data suggests that blocking IL-38 could potentially reverse immune suppression in tumors, providing a promising avenue for cancer treatment.

Immunome, Inc. (NASDAQ: IMNM) announced an oral poster presentation of its anti IL-38 antibody program at the 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, scheduled for October 7-10, 2021. The presentation, titled “IMM20324, a first-in-class, anti-interleukin-38 monoclonal antibody,” will cover the antibody's effectiveness in inducing robust anti-tumor responses in vivo. This marks a significant milestone for Immunome as it advances its therapeutic programs targeting oncology and infectious diseases, including COVID-19.

Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company focused on antibody therapeutics, announced that President and CEO Purnanand Sarma, Ph.D., will present at the Cantor Global Healthcare Conference on September 29, 2021, at 8:40 a.m. ET. Interested parties can access the live audio webcast through the company's Investor Relations page. Immunome leverages its human memory B cell platform to develop first-in-class therapeutics targeting oncology and infectious diseases, including COVID-19.